The cardiotoxicity of chemotherapy

New prospects for an old problem

GianMaria Miolo, Nicoletta La Mura, Paola Nigri, Antonio Murrone, Laura Da Ronch, Elda Viel, Andrea Veronesi, Chiara Lestuzzi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Cardiotoxicity caused by chemotherapy, with its diverse early and late presentations, can hamper potentially curative or palliative treatments. The drugs most often linked to cardiotoxicity include anthracyclines, trastuzumab, 5-fluorouracil and taxanes, but some forms of cardiotoxicity have been described, more or less sporadically, for most antitumour agents. It is likely that the widespread use of the new biological target therapies will lead to the identification of other less known toxic effects. The available data on its incidence and clinical presentation, the pathogenetic mechanisms involved, the diagnosis, prevention and management of cardiac toxicity from chemotherapy are briefly reviewed. Conclusions. The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease. It will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Further studies will therefore be necessary.

Original languageEnglish
Pages (from-to)149-161
Number of pages13
JournalRadiology and Oncology
Volume40
Issue number3
Publication statusPublished - 2006

Fingerprint

Drug Therapy
Taxoids
Biological Therapy
Poisons
Anthracyclines
Palliative Care
Fluorouracil
Pharmaceutical Preparations
Antineoplastic Agents
Cardiotoxicity
Incidence
Therapeutics
Trastuzumab

Keywords

  • Antineoplastic agents - adverse effects - toxicity
  • Heart - drug effects

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Miolo, G., La Mura, N., Nigri, P., Murrone, A., Da Ronch, L., Viel, E., ... Lestuzzi, C. (2006). The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiology and Oncology, 40(3), 149-161.

The cardiotoxicity of chemotherapy : New prospects for an old problem. / Miolo, GianMaria; La Mura, Nicoletta; Nigri, Paola; Murrone, Antonio; Da Ronch, Laura; Viel, Elda; Veronesi, Andrea; Lestuzzi, Chiara.

In: Radiology and Oncology, Vol. 40, No. 3, 2006, p. 149-161.

Research output: Contribution to journalArticle

Miolo, G, La Mura, N, Nigri, P, Murrone, A, Da Ronch, L, Viel, E, Veronesi, A & Lestuzzi, C 2006, 'The cardiotoxicity of chemotherapy: New prospects for an old problem', Radiology and Oncology, vol. 40, no. 3, pp. 149-161.
Miolo G, La Mura N, Nigri P, Murrone A, Da Ronch L, Viel E et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiology and Oncology. 2006;40(3):149-161.
Miolo, GianMaria ; La Mura, Nicoletta ; Nigri, Paola ; Murrone, Antonio ; Da Ronch, Laura ; Viel, Elda ; Veronesi, Andrea ; Lestuzzi, Chiara. / The cardiotoxicity of chemotherapy : New prospects for an old problem. In: Radiology and Oncology. 2006 ; Vol. 40, No. 3. pp. 149-161.
@article{f2666951213e4ac6b0c8bd65d2761805,
title = "The cardiotoxicity of chemotherapy: New prospects for an old problem",
abstract = "Background. Cardiotoxicity caused by chemotherapy, with its diverse early and late presentations, can hamper potentially curative or palliative treatments. The drugs most often linked to cardiotoxicity include anthracyclines, trastuzumab, 5-fluorouracil and taxanes, but some forms of cardiotoxicity have been described, more or less sporadically, for most antitumour agents. It is likely that the widespread use of the new biological target therapies will lead to the identification of other less known toxic effects. The available data on its incidence and clinical presentation, the pathogenetic mechanisms involved, the diagnosis, prevention and management of cardiac toxicity from chemotherapy are briefly reviewed. Conclusions. The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease. It will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Further studies will therefore be necessary.",
keywords = "Antineoplastic agents - adverse effects - toxicity, Heart - drug effects",
author = "GianMaria Miolo and {La Mura}, Nicoletta and Paola Nigri and Antonio Murrone and {Da Ronch}, Laura and Elda Viel and Andrea Veronesi and Chiara Lestuzzi",
year = "2006",
language = "English",
volume = "40",
pages = "149--161",
journal = "Radiology and Oncology",
issn = "1318-2099",
publisher = "Slovenian Medical Society / Croatian Medical Association",
number = "3",

}

TY - JOUR

T1 - The cardiotoxicity of chemotherapy

T2 - New prospects for an old problem

AU - Miolo, GianMaria

AU - La Mura, Nicoletta

AU - Nigri, Paola

AU - Murrone, Antonio

AU - Da Ronch, Laura

AU - Viel, Elda

AU - Veronesi, Andrea

AU - Lestuzzi, Chiara

PY - 2006

Y1 - 2006

N2 - Background. Cardiotoxicity caused by chemotherapy, with its diverse early and late presentations, can hamper potentially curative or palliative treatments. The drugs most often linked to cardiotoxicity include anthracyclines, trastuzumab, 5-fluorouracil and taxanes, but some forms of cardiotoxicity have been described, more or less sporadically, for most antitumour agents. It is likely that the widespread use of the new biological target therapies will lead to the identification of other less known toxic effects. The available data on its incidence and clinical presentation, the pathogenetic mechanisms involved, the diagnosis, prevention and management of cardiac toxicity from chemotherapy are briefly reviewed. Conclusions. The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease. It will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Further studies will therefore be necessary.

AB - Background. Cardiotoxicity caused by chemotherapy, with its diverse early and late presentations, can hamper potentially curative or palliative treatments. The drugs most often linked to cardiotoxicity include anthracyclines, trastuzumab, 5-fluorouracil and taxanes, but some forms of cardiotoxicity have been described, more or less sporadically, for most antitumour agents. It is likely that the widespread use of the new biological target therapies will lead to the identification of other less known toxic effects. The available data on its incidence and clinical presentation, the pathogenetic mechanisms involved, the diagnosis, prevention and management of cardiac toxicity from chemotherapy are briefly reviewed. Conclusions. The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease. It will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Further studies will therefore be necessary.

KW - Antineoplastic agents - adverse effects - toxicity

KW - Heart - drug effects

UR - http://www.scopus.com/inward/record.url?scp=33750087273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750087273&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 149

EP - 161

JO - Radiology and Oncology

JF - Radiology and Oncology

SN - 1318-2099

IS - 3

ER -